Entries by Infixion Bioscience

iNFixion Bioscience completes NIH I-Corps™ commercialization program

The core team at iNFixion Bioscience has successfully completed the prestigious NIH I-Corps™ commercialization program.  In addition to a commercialization curriculum, the program included teh requirement of conducting interviews with over 100 people from across the NF1 and Rare Drug ecosystems.  These interviews included: Adults with NF1, NF1 parents, NF clinic directors and specialists, rare […]

iNFixion Bioscience announces effort to develop new NF1 monoclonal antibody

iNFixion Bioscience announced today its commitment to developing a new monoclonal antibody against NF1 protein. This NF1-specific reagent will be developed in rabbits using full-length NF1 protein as the immunogen, with the program goal being to establish a more sensitive and specific NF1 monoclonal antibody than is commercially available today. This NF1 research tool, once […]